Impact of COVID-19 on Influenza Vaccine Sales in France, United Kingdom and United States

Author(s)

Ngami A1, Christie T2, Ménin G3, Guelfucci F1, Bianic F1, Net P1
1Syneos Health, Montrouge, France, 2Syneos health, Singapore, Singapore, 3Sanofi Pasteur, Lyon, France

Presentation Documents

OBJECTIVES : Because of the COVID-19 pandemic, immunization against influenza for the 2020/21 season was paramount and many governments strengthened their influenza vaccination policies to protect their populations and spare their healthcare systems. The objective of this study was to evaluate the impact of COVID-19 on influenza vaccines sales.

METHODS : We focused on influenza vaccine sales or prescription/reimbursement for the influenza seasons 2015/16 to 2020/21 in France, UK and US. All influenza vaccine presentations were considered based on national recommendations for immunization. Data was collected for each season from September/October to January/February as we assumed vaccines could be administered during this period. Data for France and UK was extracted from the Assurance Maladie and the Vantage IQ databases that provide reimbursement and prescription data respectively. Finally, the CDC website provided the number of doses distributed in the US. We used non-parametric Wilcoxon signed-rank tests to investigate significant vaccine sales variations for the 2020/21 season compared to previous seasons

RESULTS : In France, 10.8 million doses were reimbursed in 2020/21, representing an overall increase of +33.6% compared to previous seasons (p=0.0313). Significant increases were observed for October 2020 (+106.5%) and January 2021 (+102.6%) (p=0.0313). Similarly, 12.7 million doses were prescribed in the UK in 2020/21 i.e +7.7% versus previous seasons (p=0.0313). Likewise, increases were evident during September (+27.9%) and December 2020 (+14.5%) (p=0.0313). In the US, 193.8 million doses were distributed in 2020/21, marking a +22.5% augmentation compared to previous seasons (p=0.0313), with significant increases noted for October (+68.6%), November (+49.0%) and December 2020 (+52.9%) (p=0.0313).

CONCLUSIONS : We observed a significant increase in influenza vaccine sales for the season 2020/21 compared to previous seasons, probably in order to limit the impact of a Sars-CoV-2/influenza co-circulation. Vaccine sales/reimbursements for the 2021/22 season should also be investigated as the pandemic is still ongoing.

Conference/Value in Health Info

2021-11, ISPOR Europe 2021, Copenhagen, Denmark

Value in Health, Volume 24, Issue 12, S2 (December 2021)

Code

POSC402

Topic

Epidemiology & Public Health, Health Policy & Regulatory, Real World Data & Information Systems

Topic Subcategory

Health & Insurance Records Systems, Insurance Systems & National Health Care, Public Health

Disease

Respiratory-Related Disorders, Vaccines

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×